Epizyme up 12% after advisory committee nod on tazemetostat

Epizyme (EPZM +11.7%) touched $25.00 (+37%) after trading resumed following the FDA advisory committee meeting on tazemetostat but could hold the gain. Volume is closing in on 1.6M shares, up two-fold.

In an unanimous 11-0 vote, the committee backed approval for epithelioid sarcoma.

https://seekingalpha.com/news/3527217-epizyme-up-12-after-advisory-committee-nod-on-tazemetostat